Last reviewed · How we verify

dexmedetomidine-esketamine-ropivacaine combination 2

Peking University First Hospital · FDA-approved active Small molecule Quality 2/100

dexmedetomidine-esketamine-ropivacaine combination 2 is a Small molecule drug developed by Peking University First Hospital. It is currently FDA-approved. Also known as: epidural analgesia using the dexmedetomidine-esketamine-ropivacaine combination 2.

At a glance

Generic namedexmedetomidine-esketamine-ropivacaine combination 2
Also known asepidural analgesia using the dexmedetomidine-esketamine-ropivacaine combination 2
SponsorPeking University First Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about dexmedetomidine-esketamine-ropivacaine combination 2

What is dexmedetomidine-esketamine-ropivacaine combination 2?

dexmedetomidine-esketamine-ropivacaine combination 2 is a Small molecule drug developed by Peking University First Hospital.

Who makes dexmedetomidine-esketamine-ropivacaine combination 2?

dexmedetomidine-esketamine-ropivacaine combination 2 is developed and marketed by Peking University First Hospital (see full Peking University First Hospital pipeline at /company/peking-university-first-hospital).

Is dexmedetomidine-esketamine-ropivacaine combination 2 also known as anything else?

dexmedetomidine-esketamine-ropivacaine combination 2 is also known as epidural analgesia using the dexmedetomidine-esketamine-ropivacaine combination 2.

What development phase is dexmedetomidine-esketamine-ropivacaine combination 2 in?

dexmedetomidine-esketamine-ropivacaine combination 2 is FDA-approved (marketed).

Related